• To inform participants about the emerging problems related to peri-implant mucosal inflammation (PIMI)

• To highlight the possibility that PIMI might have a similar impact on general health as does periodontal disease

• To discuss potentially novel treatment modalities for management and/or prevention of PIMI

• To educate the participant as to the clinical features of refractory periodontitis

• Demonstrate unique biological markers for patients with refractory periodontitis

• To inform participants of emerging approaches for the management of refractory periodontitis

This presentation will cover several areas related to an emerging problem related to inflammatory disease about endosseous dental implants. Implants have traditionally been thought to be impervious to biofilm-induced disease but there is increasing evidence that this is not the case. There is an increasingly large burden of implants that are surrounded by inflamed mucosal tissues. While not all of these inflamed situations will lead to loss of an implant or so-called peri-implantitis, it is likely that in all cases of peri-implantitis and implant failure, there has been some predisposing or at least contributory mucosal inflammation. These issues will be discussed along with potentially new ways to measure peri-implant mucosal inflammation (PIMI) including a new classification system for this condition. The development of reliable measurements methods is critically important for the development of reliable and rational treatment and prevention of PIMI. Various measures for treatment range from the use of debridement and locally administered antimicrobials to the possible use of locally delivered bisphosphonates to regenerate bone.

Another area that will be discussed relates to refractory periodontitis. Although this condition represents a small percentage of patients who present with periodontitis, considerable efforts and cost are expended in management. Often such patients have excellent oral hygiene and yet continue to lose attachment and demonstrate other non-responsive signs of inflammatory disease. Conventional treatments including periodontal surgery are frequently inadequate for management of refractory periodontitis but are costly, painful and can lead to significant frustration as patients continue to lose bone and teeth. This part of the program will focus on biological factors that differentiate this population of patients from those with the more treatable forms of periodontitis (e.g. chronic periodontitis). New information related to host-modulation therapy that might prove useful for management of patients with refractory periodontitis will be presented and will include the use of sub-antimicrobial dose doxycycline (e.g. Periostat®) alone or in combination with flurbiprofen and even low dose ASA. By using these host modulation therapy approaches it will be shown that not only can bone loss be arrested (something never thought possible) but that there might even be a tendency for gains in clinical attachment. As well, preliminary evidence will be presented showing a reduction in markers that connote risk for cardiovascular disease in patients undergoing host-modulation therapy.

This seminar is offered to all the team.

Consult our detailed brochure by clicking on the hyperlink below. 

You are invited to contact us toll free at : 1-877-463-1281

Or e-mail us at info@idi.org

Simple on-line registration : click on the hyperlink below

Do not defer registering because attentance is limited.